NCT Number: NCT00274508
Effect of Tiotropium (Spiriva) on Exercise Tolerance in COPD Patients
To investigate whether tiotropium (Spiriva) improves exercise endurance in patients with COPD
Looking for future studies?
Notify MeKey information
Conditions
Age range
40 year–75 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 3
Primary location
Phase I Unit, Randwick, New South Wales, Australia
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Male or female patients with a clinical diagnosis of Chronic Obstructive Pulmonary Disease (COPD) based on American Thoracic Society (ATS) guidelines with:
- Relatively stable, moderate to severe airway obstruction with an Forced Expiratory Volume in One Second (FEV1) less than or equal to 65% of predicted normal (determined at Visit 1).
- Presence of lung hyperinflation as demonstrated by Functional Residual Capacity determined by body plethysmography (TGV(FRC)) greater than or equal to 120% of predicted normal (determined at Visit 1).
- Age greater or equal to 40 years and less than or equal to 75 years.
- A cigarette smoking history of more than ten pack-years. A pack-year was defined as the equivalent of smoking one pack of cigarettes per day for a year.
- Able to perform all specified procedures and able to maintain all necessary records during the study period as required in the protocol.
- Able to inhale the trial medication from the HandiHaler device.
Exclusion criteria
- Patients with a significant disease other than COPD. A significant disease was defined as a disease which, in the opinion of the investigator, may have put the patient at risk because of participation in the trial or may have influenced the results of the trial or the patient's ability to participate in the trial.
- Patients with clinically significant abnormal baseline hematology, blood chemistry or urinalysis. If the abnormality defined a disease listed as an exclusion criterion, the patient was excluded.
- Patients with Serum Glutamic Oxaloacetic Transaminase (SGOT) ≥1.5 x ULN (upper limit of normal range), Serum Glutamic Pyruvic Transaminase (SGPT) ≥1.5 x ULN bilirubin ≥1.5 x ULN or creatinine ≥1.5 x ULN were excluded regardless of the clinical condition.
- Patients with a recent history (i.e., 1 year or less) of myocardial infarction.
- Patients with a recent history (i.e., 3 years or less) of heart failure, pulmonary edema, or patients with cardiac arrhythmia (with or without symptoms) or any contraindication to exercise.
- Patients requiring the regular use of daytime oxygen therapy.
- Patients with known active tuberculosis.
- Patients with a history of cancer within the last 5 years. Patients with treated basal cell carcinoma were eligible.
- Patients with a history of life-threatening pulmonary obstruction, or a history of cystic fibrosis or bronchiectasis.
- Patients who had undergone thoracotomy with pulmonary resection. Patients with a history of thoracotomy for other reasons were evaluated as per the first exclusion criterion (i.e., significant disease other than COPD).
- Patients with an upper respiratory tract infection in the 6 weeks prior to the Screening Visit (Visit 1) or during the run-in period.
- Further exclusion criteria apply.
Treatment and study plan
Primary outcomes
-
Endurance time during a constant work rate exercise test to symptom limitation
Time frame: 2 hours and 15 minutes after trial medication administration on Day 42
Secondary outcomes
-
Constant work rate exercise test to symptom limitation
Time frame: 8 hours post-dose after 6 weeks of treatment
-
Breathing discomfort during constant work rate exercise test as measured by the modified Borg Scale
Time frame: 6 weeks
-
Dynamic lung hyperinflation during exercise as determined by IRVdyn (IC minus VT) and EELVdyn (TLC)
Time frame: 6 weeks
-
Evaluation of VE and VEcap during exercise (selected centers)
Time frame: 6 weeks
-
Evaluation of static lung hyperinflation as measured by RV/TLC and by TGV(FRC)/TLC
Time frame: 6 weeks
-
Evaluation of TAC (TAV = TLC(BOX)-VA(IG))
Time frame: 6 weeks
-
Evaluation of slow vital capacity (SVC)
Time frame: 6 weeks
-
Evaluation of maximal expiratory flow rates and volumes FEV1, FVC, FEF25-75%, FEF50%, FEF75%, SVC
Time frame: 6 weeks
-
Evaluation of TGV, Raw, SGaw and RV
Time frame: 6 weeks
-
Evaluation of SaO2, VO2, VCO2, Ti, Te, VE, VT, breathing frequency (f) during constant work rate exercise test
Time frame: 6 weeks
-
Physician's Global Assessment
Time frame: 6 weeks
-
Assessement of Pulse/heart rate and blood pressure in conjunction with spirometry and exercise
Time frame: 6 weeks
-
Changes in Physical examination and ECG
Time frame: 6 weeks
-
Occurrence of Adverse Events
Time frame: 6 weeks
Sponsors and collaborators
Lead sponsor
Boehringer Ingelheim
Industry
Registry information
Official study title
Effect of Tiotropium on Exercise Tolerance and Static and Dynamic Lung Volumes in COPD Patients (A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study)
Important dates
- Study start
- 2000
- Primary completion
- 2003
- First posted
- Jan 11, 2006
- Registry last updated
- Dec 1, 2023
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
A Phase II Clinical Trial on the Efficacy and Safety of TQC3721 Inhalation Powder
NCT07252908
Chronic Disease, Disease Attributes
Chongqing, Chognqing, China
View Trial DetailsGenerative AI for Medication Counselling and Adherence in Community Pharmacies
NCT07649577
Asthma, Bronchial Diseases
Amman, Jordan
View Trial DetailsA Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of GSK3862995B Administered as a Single Dose to Healthy Participants of Chinese, Japanese, and European Ancestry
NCT06979518
Chronic Disease, Disease Attributes
Cypress, California, United States
View Trial DetailsDetecting Systemic Carbon Dioxide Levels With a Novel Biosensor
NCT06367686
Apnea, Chronic Disease
Tønsberg, Norway
View Trial Details